Big pharma stocks have surged behind the market's rally, but that doesn't mean that every company in this top health care industry's performing up to healthy standards. Between the patent cliff and the latest China bribery scandal, several top pharmaceutical companies have endured a tough stretch of setbacks lately that could haunt their stocks in 2014.
GlaxoSmithKline's (NYSE:GSK) been at the center of the China scandal through the second half of 2013, and while the company expects to bounce back in the world's second-largest economy this year, is GlaxoSmithKline on track to recover from a 61% drop in China sales in the third quarter? Meanwhile, both Eli Lilly (NYSE:LLY) and AstraZeneca (NYSE:AZN) suffer from lackluster pipelines and withering losses from patent expirations, with their respective drugs Cymbalta and Nexium poised to experience patent cliff-related drop-offs this year.
Despite these looming dangers, can long-term investors unearth real value out of these seemingly hard-hit companies? In the video below, Motley Fool contributor Dan Carroll tells you how GlaxoSmithKline, AstraZeneca, and Eli Lilly could pan out in 2014-and whether or not these three stocks are worth a look for your portfolio.
Are the best dividends in big pharma?
Big pharma stocks like GlaxoSmithKline long have been known for their dividend potential in the long-term, even in periods of struggling growth, but the best income investors know the power of diversifying their dividends. If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.